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Abstract  
Background 
Hepatitis-B virus (HBV) has a detrimental effect on HIV natural course, and HBV 
vaccination is less effective in the HIV infected. We examine the protective effect of dually 
active antiretroviral therapy (DAART) for HIV/HBV (Tenofovir/Lamivudine/Emtricitabine) 
in a large cohort encompassing heterosexuals, men-who-have-sex-with-men (MSM), and 
intravenous drug users (IDU), who are HIV-infected yet susceptible to HBV, with 
comprehensive follow-up data about risky behavior and immunological profile.  
Methods 
We defined an incident HBV infection as the presence of any of HBV serological markers 
(HBsAg/AntiHBc/HBV-DNA) following a negative baseline AntiHBc test. Patients with 
positive AntiHBs were excluded. Cox proportional hazard models were utilized, with an 
incident case of HBV infection as the outcome variable. 
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Results 
We analyzed 1,716 eligible patients from the Swiss HIV Cohort Study with 177 incident 
HBV cases. DAART was negatively associated with incident HBV infection (hazard ratio 0.4, 
95%CI 0.2-0.6). This protective association was robust to adjustment (0.3, 0.2-0.5) for 
condomless sex, √CD4 count, drug use, and patients’ demographics. Condomless sex 
(1.9,1.4-2.6), belonging to MSM (2.7,1.7-4.2) or IDU (3.8,2.4-6.1) were all associated with 
higher HBV hazard. 
Conclusions 
Our study suggests that DAART, independently of CD4 count and risky behavior, has a 
potentially strong public health impact including pre-exposure prophylaxis of HBV co-
infection. 
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The prevention of Hepatitis B virus (HBV) transmission in HIV infected individuals is 
important as both viruses share common transmission modes and both HIV and HBV have 
detrimental effects on each other’s natural course of infection [1-3]. HBV is a worldwide 
leading cause of chronic hepatitis, responsible for roughly one half of hepatocellular 
carcinoma deaths, and one third of liver cirrhosis related mortality [4]. It is estimated that 
globally, HBV affects 10% of all HIV-1 infected individuals [5,6]. In addition, HBV and 
hepatitis C virus taken together are responsible for ~15% of mortality in HIV patients in the 
Swiss HIV Cohort Study (SHCS)[7]. 
 
 
Vaccination against HBV remains the mainstay of preventing HBV acquisition both in HIV 
infected and uninfected individuals. However, owing to HIV’s effect on the immune system, 
mounting and maintaining a protective immune response against HBV is sometimes 
unattainable with a success rate between 18% and 71% [8, 9, 10].  
 
 
Taken together with the unfavorable course of HIV/HBV co-infections, it is of great public 
health value to prevent HBV acquisition in HIV patients. Earlier studies focused on the 
protective effect of dually acting HIV-1 antiretroviral drugs (Tenofovir (TDF), Lamivudine 
(3TC), and Emtricitabine (FTC)) [11–14] against HBV, mainly in men who have sex with 
men (MSM). Considering that heterosexual transmission remains the main driver of HIV 
propagation in sub-Saharan Africa and many parts of Asia [15] and that  intravenous drug use 
(IDU) is responsible of 30% of HIV cases outside of sub-Saharan Africa [16], and that the 
highest HBV burden lies in sub-Saharan Africa and south east Asia [17], it is of great 
importance to evaluate the protective effect of DAART in all of these three major 
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transmission groups.  Consequently, in this study we examine the effect of dually acting 
HIV/HBV antiretrovirals (DAART) containing regimens (TDF, 3TC, and FTC) in protecting 
against incident HBV infections in HET, MSM, and IDU. Our study has one of the largest 
number of HBV susceptible HIV-positive individuals and incident cases examined so far in 
the context of ART protective effect and it is unique in its generalizability as it considers the 
three main transmission-groups. Using the SHCS’s comprehensive longitudinal data on 
patients’ sexual behavior, drug use, immunological and antiretroviral treatment status, we aim 
to quantify DAART’s effect and discern the effects of the aforementioned factors from 
DAART’s direct one, which would provide a more concrete estimate on the degree of 
protection DAART confers against incident HBV infections. A strong protective effect would 
call for early treatment initiation and, especially, for favoring regimens containing DAART in 
settings where vaccination rates or vaccination success are low and where HBV is common. 
We hypothesize that DAART has a protective effect against HBV but that the magnitude of 
the association could be modified, masked, or confounded by behavioral, demographic, and 
immunological factors.  
 
Methods 
The Patients 
The Swiss HIV Cohort Study (SHCS) is an ongoing, prospective, national observational 
cohort study with biannual follow-ups that started in 1988. Written informed consent was 
obtained from all patients. CD4 and CD8 cell count, and HIV-1 viral load are collected 
continuously (during follow up visits, in general every 3 months). In addition, antiretroviral 
treatment history is recorded since the first ART drugs are available in Switzerland. Age, 
transmission group and ethnicity are recorded as well as condom usage. In particular, at each 
of the biannual follow-up visits, individuals were asked if in the preceding 6 months (a) they 
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had occasional partners, (b) they had sex with an occasional partner, and (c) how often they 
used condoms. The SHCS has an excellent coverage with more than 70% of patients on ART 
in Switzerland [7]. 
 
The study population included all HIV-1 infected individuals taking part in the SHCS from 
1992 to 2014 who were tested for at least one of the following HBV markers: Hepatitis B 
surface Antigen (HBsAg), Anti-Hepatitis B core antibodies (AntiHBc), or Hepatitis B Virus-
DNA. Next, patients positive for any of the aforementioned HBV markers at baseline were 
excluded from the analysis (borderline tests were considered positive). Successful vaccination 
is highly protective against HBV infection. Accordingly, patients with positive AntiHBs 
antibodies at baseline were excluded. For patients who developed positive AntiHBs 
antibodies during their follow-up time, only the time at risk before the first positive AntiHBs 
test was included. An incident case was then defined to be a person in whom any of the three 
HBV markers of interest turned positive following at least a negative AntiHBc at baseline.  
 
An isolated antiHBc has been linked to several factors including the assay method, the viral 
strain, and the immunological status of the patient [18] and its clinical and physiological 
significance remains unclear. Hence, we performed a sensitivity analysis excluding patients 
with isolated antiHBc serology to assess the robustness of the associations.  
 
In all analyses only patients with an observation time longer than 6 months were examined. 
 
Statistical Methods 
Both univariable and multivariable Cox-proportional-hazard regression models were utilized 
to address our hypothesis. The outcome variable in the analysis was an incident case of HBV 
infection, and the main explanatory variable was the proportion of observation time on ART 
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calculated by dividing the number of months the patients was on ART over the number of 
months the patient was observed (later further subdivided into individual DAART and ART 
regimens). In a sensitivity analysis we also examined the proportion of observation time on 
ART while an individual is suppressed (i.e. viral load <400 copies/ml) and non-suppressed. 
Given the longitudinal nature of the data and the fact that outcome variable (HBV infection) 
cannot be observed exactly (contrary for example to death), a sensitivity analysis was 
performed using a parametric interval censored model with time varying covariates [19] (see 
supplementary material for method, R-code, and simulated data). 
 
 
The covariates tested were the closest CD4 and CD8 cell count to infection or censoring time, 
since both are implicated in the natural course of both HBV and HIV [20,21]. Both CD4 and 
CD8 counts were square root transformed since this provides more normally distributed 
values and variance stabilization. Having had unprotected sex (occasional or with stable 
partner) as reported by the patient (during the follow up time before censoring or the event) 
was taken as a proxy for patient’s risky behavior. In addition, baseline CD4, CD8 cell count, 
age at enrollment, history of drug use, ethnicity, and sex with transmission group (with the 
following categories: Male-HET, Female-HET, Male-MSM, Male-IDU, Female-IDU). In 
addition, we also considered the nadir CD4 cell count calculated as the lowest CD4 cell count 
observed during the observation time for the individual patient.
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Results 
Starting with all SHCS patients registered (December 2014) (N = 18,663), we kept only 
patients with a negative baseline HBV serology, at least another test after baseline, and who 
belonged to one of the major transmission groups (MSM, HET, and IDU) (N = 1,716), Figure 
1. The risk group distribution was 936 HET (54%), 220 IDU (13%) and 612 MSM (33%). 
4,532 individuals were excluded due to the unavailability of their HBV tests, said patients 
were mostly recruited early in the cohort (median 1990, IQR 1988-1992) and 95% died or 
were lost to follow up by 1996. 
 
 
The total number of incident HBV cases was 177 of which 49% (86 cases) were in MSM. 
Patients’ observation time started from the date of the first negative test and ended at the last 
time the patient was tested or if an event occurred. Most patients had only two tests (N = 
1,129, 66%) (IQR 2-3), and the median time between tests was 29 months (IQR 12-58), Table 
1. The total observation time was 10,682 person years. The overall incidence rate (IR) per 
thousand person years was (16, 95%CI 14-19). The transmission group incidence rate was as 
follows: HET (IR 9, 95%CI 6-11), IDU (IR 28, 95%CI 21-38), and MSM (IR 25, 95%CI 21-
31) per thousand person years. 
 
 
Both univariable and multivariable analysis showed a strong risk reduction of acquiring HBV 
for patients on DAART. In univariable analysis DAART had a protective effect against HBV 
acquisition with a Hazard ratio (HR) of 0.4 (95%CI 0.2-0.6), while other ART regimens had 
none (HR 1.63, 95%CI 0.94-2.81) (Figure 2 and Table 2). Furthermore, the exclusion of 
patients with isolated positive antiHBc serology did not affect the associations (HR 0.4, 
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95%CI 0.2-0.8). The proportion of time on DAART while HIV-RNA viral load is below 400 
showed similar protective effect (HR 0.4, 95%CI 0.2-0.6), while being on DAART but not 
suppressed had no significant protection (HR 0.6, 95%CI 0.2-1.7). Other non-DAART 
antiretrovirals showed no protective effect even with suppression (HR 1.4, 95%CI 0.70-2.7), 
moreover being on non-DAART regimens and not suppressed was associated with higher 
HBV incidence (HR 3.4, 1.2-10.0), but this association was not significant in the 
multivariable model (multivariable HR 2.0, 95%CI 0.5-7.5). The log-likelihood ratio test 
showed no significant difference between the unadjusted model with DAART only and the 
model with DAART conditional on suppression (P-Value: 0.3), however the difference was 
borderline significant when comparing the adjusted models (P-Value: 0.055). 
 
 
The univariable analysis also demonstrated a higher burden of incident cases in MSMs and 
IDU compared to HET (Table 2). Compared to heterosexual males, heterosexual females had 
lower odds of acquiring HBV (HR 0.5, 95%CI 0.3-1.0). 
  
 
Self-reported risky sexual behavior was associated with higher risk of acquiring HBV. 
History of condomless sex was associated with higher HBV acquisition risk (HR 1.9, 95%CI 
1.4-2.6), while having used intravenous drugs at any point during the observation time did not 
play a role (HR 1.0, 95%CI 0.2-3.8).  
 
 
We examined the closest √CD4 count value to the HBV co-infection date as a proxy for 
immune-mediated effect of ART on HBV, and a protective association was observed, yet not 
statistically significant (HR 0.98, 95%CI 0.96-1.002). Neither the baseline √CD4 cell count 
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nor √CD8 cell count had an influence on the risk of HBV acquisition. Using non square root 
transformed values of CD4 and CD8 cell counts did not alter the associations.  
 
 
One notable observation was the stronger protective effect of DAART in patients with CD4 
nadir >=200 x 106 cells/ml (635 patients, 38%). In those patients DAART’s protective effect 
was (HR 0.2, 95%CI 0.1-0.5) in the univariable model and (HR 0.1, 95%CI 0.1-0.4) in the 
multivariable one. DAART also had a protective effect in patients with CD4 nadir <200 106 
cells/ml (1062 patients, 62%) yet only significant in the univariable model (univariable HR 
0.5, 95%CI 0.3-0.8; multivariable HR 0.5, 95%CI 0.2-1.1). The difference in DAART’s effect 
between patients with CD4 nadir => 200 and <=200 was not statistically significant in a 
multivariable Cox model with an interaction term between the proportion of time on DAART 
and nadir CD4. 
 
 
The adjusted analysis displayed the same irection of association in terms of the protective 
effect of DAART (HR 0.3, 95%CI 0.2-0.6) (Table 2). √CD4 was not significant in the 
multivariable model (HR 1.0, 95%CI 0.98-1.03), while condomless sex remained significant 
(HR 1.9, 95%CI 1.4-2.6). The protective association of DAART was not affected by adjusting 
for these variables. The protective association of DAART was also robust to model choice, 
evident by a sensitivity analysis using an interval censored parametric survival model with an 
exponential hazard function and fixed and time varying covariates (univariable HR 0.5, 95% 
CI 0.3-0.6, adjusted HR 0.5, 95% CI 0.4-0.7). 
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In univariable analysis, the hazard of HBV acquisition for patients on two DAART (TDF/3TC 
and TDF/FTC) was half that of patients on one DAART (TDF alone or 3TC alone, FTC was 
not prescribed alone) (unadjusted HR two DAART 0.2, 95%CI 0.1-0.6; unadjusted HR one 
DAART 0.4, 95%CI 0.3-0.7). The protective effect of dual therapy was further strengthened 
after adjustment (adjusted HR two DAART 0.1, 95%CI 0.0-0.3; adjusted HR one DAART 
0.4, 95%CI 0.2-0.6). We tested the statistical significance of the reduction of risk for two 
versus one DAART regimens by the likelihood-ratio test, and obtained P-Values of 0.2 and 
0.01 for the univariable and the adjusted model respectively. 
 
 
After demonstrating an overall strong protective effect of DAART against HBV coinfections 
we went further to disentangle the effects of the different DAART regimens (Table 3). 
DAART regimens containing TDF in combination with 3TC or FTC displayed the strongest 
protective effect against HBV (adjusted HR 0.03, 95%CI 0.0-0.4) and (adjusted HR 0.2, 
95%CI 0.1-0.5) respectively. Furthermore, DAART regimens containing 3TC (as the only 
dually-active substance) were comparable to regimens with TDF (as the only dually-active 
substance) (Table 3). TDF only containing regimens had wide confidence intervals because of 
the short observation time patients were on TDF monotherapy. In the unadjusted model there 
was no statistically significant difference in the log-likelihood ratio test comparing all 
DAART combined versus individual DAART regimens (P-value: 0.1), while the difference 
was statistically significant in the adjusted model P-Value: 0.01).
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Discussion 
In this study we analyzed a large cohort of HIV-1 infected individuals at risk of acquiring 
HBV, in order to evaluate the protective effect of DAART in the three major HIV 
transmission groups (HET, IDU, MSM). We confirm earlier reports about the protective 
effect of dually acting anti-retroviral drugs and we report a strong protective effect of all 
DAART [11–14] in said risk groups. We also show that risky sexual behavior plays a key role 
in the acquisition of HBV infection as it independently increases the risk even in patients on 
DAART; however, it does not seem to be a confounder of DAART’s protective effect. 
Finally, we found that the immune status close to infection time as measured by CD4 was not 
a main actor in influencing the risk of acquiring HBV for patients on DAART. However, 
patients with a better long term immunological status (represented by nadir CD4 >= 200) had 
a higher protective effect of DAART. 
 
 
Our study confirms the importance of viral suppression (and the implicit adherence) in 
reaching the protective effect of DAART [11]. We observed that the protective effect of 
DAART was absent in the phases where individuals were not virologically suppressed. This 
further underlines a direct effect of DAART since treatment failure is associated with poor 
adherence [22,23] and generally with low plasma levels of drugs. For non-DAART regimens 
we found an increase in the hazard of an HBV infection in non-suppressed individuals, 
however this association was not robust to adjustment (multivariable HR 2.0, 95% CI 0.5-
7.5). On a speculative note, this could reflect the fact that lower adherence is associated with 
more risky behavior [24,25] and hence a higher HBV incidence.  
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The lack of a statistically significant difference in the LLR between the model with 
suppression and without could indicated a power issue given the short periods patients are 
usually not suppressed (and on DA/ART). This is further supported by the fact that the 
likelihood ratio test was borderline significant (P-Value 0.055) in comparing the adjusted 
models. Fortunately, 96% of patients on ART in the SHCS are suppressed, consequently, this 
problem is less concerning in our setting [26]. The UNAIDS Gap Report shows that 76% of 
patients on ART achieved viral suppression, yet the bigger problem remains that 47% of the 
HIV-infected are unaware of their positive status[16].  
 
 
Our findings also suggest that dual DAART regimens (i.e. TDF plus FTC or 3TC) are 
superior to single DAART regimens in protecting against incident HBV. This finding my be 
relevant for optimizing ART-regimes in settings where HBV incidence is high and 
vaccination coverage or response is low. One caveat to be aware of is that the majority of 
observation time on one drug was on 3TC, with the observation time on TDF alone being 
much shorter (no patient was prescribed FTC alone).  Thus, it is plausible that the observed 
enhancement of protection is due to TDF. The likelihood ratio test showed that this difference 
was only present in the adjusted model implying that other factors (such as immunological 
status and risk behavior) could have confounded the association in the unadjusted model. 
 
   
Previous studies [12,14] suggest a superior protection of TDF over 3TC containing regimens. 
We did not observe a clear superiority of TDF over 3TC regimens in our data, evident by the 
likelihood ratio test and the overlapping confidence intervals of the respective regimens. 
However, this could be due to the different ways treatment was accounted for in the different 
studies. Gatanaga et al. [14] pooled TDF+FTC regimens along with other TDF regimens and 
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did not encode the treatment as proportion of observation time, while Heuft et al. [12] adopted 
treatment averaging with categorization (detailed in the following paragraph). 
 
 
As with all observational studies there are limitations to ours. The longitudinal and periodic 
nature of the data collection gives rise to uncertainty in knowing the precise infection date of 
HBV (Figure S1). Interval censored models with time varying covariates account for this 
varying exposure (i.e. treatment changes). However, these models are scarcely described or 
used in the literature [19]. Heuft et al. shared the same concerns about the interval censored 
nature of the data [12], yet they circumvented this problem by coding for the different 
treatments as proportion of observation time on the respective treatments with <20% equaling 
to no treatment, and larger is equivalent to being on a certain treatment. This method of 
handling treatment indeed avoids some of the problems of the treatment changes and 
interruptions, but remains problematic as patients on 21% DAART are treated as those on 
100% (as discussed in [12]).  
 
In order to further assess the issue of unknown HBV infection times we considered a 
parametric survival model with fixed and time varying covariates. This model showed a 
similar protective effect of ART though the magnitude was slightly smaller than the Cox 
proportional hazard model. The estimates of both models are in line with earlier reports [11–
14].  
 
Data on HBV incidence in Switzerland remains scarce, however it is plausible that it is on the 
decline as vaccination against HBV ramped up and better harm reduction interventions were 
employed for IDU, particularly needle exchange programs [27]. In order to account for this 
potential confounding, we performed a sensitivity analysis correcting for calendar time and 
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the protective effect of DAART remained robust (unadjusted HR 0.4, 95%CI 0.2-0.6; 
adjusted HR 0.3, 95%CI 0.2-0.5).  
 
 
Black ethnicity remains underrepresented in studies addressing the protective effect of ART 
against. Both our study and that of Heuft et al. [12] take place in a majorly white population 
while that of Gatanaga et al [14] and Sheng et al. [13] are both comprised of an Asian 
majority. The consistency of the findings in previously conducted studies and ours suggest 
that the findings are independent of ethnicity. Moreover given the evidence and plausibility of 
a direct drug mediated effect, it is also unlikely that this protection depends on ethnicity. 
 
 
In our analysis 70 patients were considered positive evident by an isolated antiHBc serology 
only. The exclusion of those patients did not alter the protective DAART association (data not 
shown), suggesting that this serological profile is probably caused by HIV co-infection 
[18,28] and not by false positive lab tests as some studies suggested [18]. The isolated 
antiHBc in the HIV infected usually alludes to a recently resolved infection with low or 
undetected AntiHBs. 
 
One interesting population that we were not able to examine, is patients who were vaccinated 
but did not mount an immune response. Such an analysis was not possible using the SHCS 
dataset, as the SHCS does not collect vaccination records of the patients. 
 
One modeling study concluded [29] that even if vaccination uptake were to be 100% by all 
susceptible patients, a large fraction of patients would remain at risk of HBV acquisition, 
namely owing to the lower vaccination response in HIV patients. Hence, our retrospective 
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observational study suggests that DAART -after additional confirmation in a randomized-
controlled setting- might be worth serious consideration as an additional weapon in the 
arsenal of fighting HBV infections in HIV patients in general, and especially in settings where 
HBV vaccination uptake is low. Moreover, our study adds to the growing body of evidence 
that early antiretroviral therapy initiation [30], regardless of CD4 counts, has a strong 
beneficial public health impact, including pre-exposure prophylaxis of HBV co-infections. 
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Figures captions 
 
Figure. 1 Patients selection flowchart 
 
 
 
Figure. 2 The hazard ratios of the different factors influencing HBV incidence. Adjusted 
models co-variates shown in Table 2, column 2.  *Proportion of observation time. DAART: 
Dually Active Antiretrovirals, ART: HIV only Antiretrovirals (ART).  
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Table 1 Baseline characteristics of the 1716 patients eligible for the study based on their HBV status 
 Patients with an 
incident HBV infection 
(N. = 177) 
Patients with no incident HBV 
infection (N. = 1539) 
Sex   
Male 141 (80) 971  (63) 
Female 36 (20) 568 (37) 
Transmission group   
HET 49 (28) 887 (58) 
IDU 42 (24) 178 (12) 
MSM 86 (48) 474 (31) 
CD4+ cell count, cells/mm3, median (IQR)  429 (265-636) 432 (271-625) 
Age at registration in years , median (IQR) 33 (27-38) 33 (28-40) 
HIV-1 RNA, log10 copies/mL, median (IQR) 3.5 (2.1-4.7) 3.4 (2.0-4.4) 
Ethnicity    
White 151 (85) 1246 (81) 
Black 10 (6) 170 (11) 
Hispano-American 6 (3) 52 (3) 
Asian 6 (3) 30 (2) 
Other/Unknown 4 (3) 41 (3) 
Percentage of observation time on treatment, 
median (IQR) 
  
DAART  35 (0-80) 60 (15-94) 
non-DAART   0 (0-30) 0   (0-14) 
Year of enrollment, median (IQR) 1996 (1992-2001) 1998 (1994-2003) 
N. of tests, media (IQR) 2 (2-2) 2 (2-3) 
Observation time in months, media (IQR) 59 (32-99) 66 (34-111) 
History of drug use (%) 2 (1%) 16 (1%) 
ART start year, median (IQR) 1997 (1996-2002) 1998 (1996-2004) 
Infection year, median (IQR) 2006 (2002-2010) - 
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Table 2. Univariable and Multivariable Cox proportional hazard models for the effect of DAART and ART on 
the acquisition of HBV (bold signifies a P-Value < 0.05) 
 Univariable Analysis  Multivariate Analysis 
Complete cases only (N. = 
1,697) 
Proportion of observation time on treatment   
DAART 0.38 (0.25-0.58) 0.32 (0.18-0.58) 
ART 1.63 (0.94-2.81) 1.12 (0.55-2.30) 
Sex interaction with transmission group   
Male-HET 1 (Reference) 1 (Reference) 
Male-IDU 2.67 (1.57-4.53) 2.81 (1.56-5.06) 
Male-MSM 2.24 (1.46-3.44) 2.33 (1.46-3.72) 
Female-HET 0.55 (0.31-0.97) 0.47 (0.25-0.88) 
Female-IDU 2.01 (1.07-3.77) 2.71 (1.38-5.31) 
Ethnicity   
White 1 (Reference) 1 (Reference) 
Black 0.62 (0.33-1.18) 1.52 (0.71-3.26) 
Hispano-American 1.03 (0.46-2.34) 1.53 (0.66-3.53) 
Asian 1.77 (0.78-4.01) 2.37 (0.96-5.85) 
Other/Unknown 1.38 (0.51-3.74) 1.18 (0.42-3.31) 
Age at cohort enrollment 1.00 (0.98-1.02) 1.01 (0.99-1.03) 
History of Condomless sexa 1.92 (1.41-2.61) 1.89 (1.36-2.63) 
Registration year 1.04 (1.01-1.07) 1.06 (1.03-1.10) 
√CD4 count at test time 0.98 (0.96-1.00) 1.00 (0.98-1.03) 
√CD8 count at test timeb 1.01 (0.99-1.03) 1.00 (0.98-1.03) 
√baseline CD4 count  1.00 (0.92-1.01) 0.98 (0.95-1.00) 
History of Intravenous drug used 0.92 (0.23-3.73) - 
a (17 missing values) 
b (3 missing values) 
d Excluded for possible collinearity with IDU transmission group 
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Table 3 Univariable and Multivariable Cox regression of the effect of different ART regimens on the 
acquisition of HBV (bold signifies a P-Value < 0.05) 
  
  Univariable Analysis  Multivariate Analysis 
Complete cases only (N. = 
1,697) 
Proportion of observation time on treatment   
TDF 0.56 (0.12-2.56) 0.23 (0.04-1.14) 
3TC 0.42 (0.28-0.68) 0.41 (0.22-0.75) 
TDF+3TC 0.02 (0.00-0.34) 0.03 (0.00-0.43) 
TDF+FTC 0.42 (0.14-1.22) 0.16 (0.05-0.55) 
Other ART regimens 1.02 (0.57-1.80) 1.17 (0.57-2.40) 
Sex interaction with transmission group   
Male-HET 1 (Reference) 1 (Reference) 
Male-IDU 2.67 (1.57-4.53) 2.83 (1.57-5.09) 
Male-MSM 2.24 (1.46-3.44) 2.33 (1.46-3.71) 
Female-HET 0.55 (0.31-0.97) 0.47 (0.25-0.88) 
Female-IDU 2.01 (1.07-3.77) 2.69 (1.37-5.26) 
Ethnicity   
White 1 (Reference) 1 (Reference) 
Black 0.62 (0.33-1.18) 1.50 (0.70-3.22) 
Hispano-American 1.03 (0.46-2.34) 1.55 (0.67-3.60) 
Asian 1.77 (0.78-4.01) 2.35 (0.95-5.81) 
Other/Unknown 1.38 (0.51-3.74) 1.18 (0.42-3.29) 
Age at cohort enrollment  1.00 (0.98-1.02) 1.01 (0.99-1.03) 
History of Condomless sexa 1.92 (1.41-2.61) 1.96 (1.41-2.73) 
Registration year 1.04 (1.01-1.07) 1.08 (1.04-1.11) 
√CD4 count at test time 0.98 (0.96-1.00) 1.00 (0.97-1.03) 
√CD8 count at test timeb 1.01 (0.99-1.03) 1.00 (0.98-1.02) 
√baseline CD4 count  1.00 (0.92-1.01) 0.98 (0.96-1.00) 
a (17 missing values) 
b (3 missing values) 
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